Restart Life - NMLSF STOCK NEWS

Nova Mentis Life Science Corp. appoints Steve Loutskou, a seasoned serial entrepreneur, to its Board of Directors. With over 20 years of experience, Mr. Loutskou brings expertise in business management, operations, and financing, promising to shape Nova's future with innovative strategies and financial acumen.

Nova Mentis Life Science Corp. applauds the Canadian government for establishing a new Implementation Advisory Group (IAG) for drugs for rare diseases. The government will make up to $1.4 billion available to provinces and territories to improve access and affordability of effective drugs for rare diseases. Nova Mentis is dedicated to improving the quality of life for those with fragile x syndrome (FXS) and is conducting a human trial investigating the effects of psilocybin on FXS. The company has achieved orphan drug designation in both the US and EU for the use of psilocybin in the treatment of FXS.

Nova Mentis provides update on Phase IIA clinical trial testing psilocybin for fragile X syndrome

Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.

Wellbeing Digital Sciences Inc. (KONEF, NMLSF) has announced that its subsidiary, KGK Sciences Inc., gained IRB approval in Canada to conduct a groundbreaking Phase IIA clinical trial. This study will test the efficacy of psilocybin on adults with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). The trial is part of a partnership with Nova Mentis Life Science Corp., aiming to assess psilocybin's impact on cognitive and behavioral symptoms. Patient recruitment is expected to begin this year. Notably, Health Canada has granted special permission for participants to take the drug home, marking a significant milestone in clinical research. This trial supports Nova's ongoing efforts to improve treatment options for FXS patients, following their FDA Orphan Drug designation received in 2021.

Wellbeing Digital Sciences Inc. (KONEF, NMLSF) announces its subsidiary, KGK Sciences, has received a Section 56 exemption to proceed with a Phase IIA clinical trial evaluating microdose psilocybin therapy for fragile X syndrome (FXS). This trial aims to study cognitive and behavioral symptoms linked to FXS, a major genetic cause of autism spectrum disorder. The study is significant as it represents a pioneering approach in this area, supported by a No Objection Letter from Health Canada. With the production of cGMP synthetic psilocybin underway, the trial seeks to enhance understanding of psilocybin's therapeutic potential, with participant recruitment starting in early 2023.

Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences has received approval from Health Canada for a Phase II clinical trial. The study will assess the efficacy of psilocybin therapy on Fragile X syndrome, a leading genetic cause of autism spectrum disorder. The open-label trial aims to recruit 10 participants and is set to begin recruiting in early 2023. The results will support Nova Mentis Life Science Corp.’s drug development program, which has FDA Orphan Drug designation.

Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences submitted a clinical trial application for a Phase IIa study testing the efficacy of psilocybin in treating cognitive and behavioral symptoms associated with Fragile X Syndrome (FXS). The trial, sponsored by Nova Mentis Life Science Corp., will assess a 1.5 mg microdose of psilocybin and is expected to begin in early 2023 pending Health Canada's approval. This study marks a significant milestone as the first human trial using psilocybin for FXS.

Wellbeing Digital Sciences (OTC: KONEF, NEO: MEDI) announced that its subsidiary KGK Science will conduct a Phase II clinical trial to evaluate the effects of psilocybin on Fragile X syndrome. This marks the first research into psilocybin microdoses for improving behavioral and cognitive symptoms associated with the disorder. The trial, which will involve 10 participants, supports Nova Mentis’ drug development efforts under FDA Orphan Drug designation. Results are aimed at addressing significant unmet medical needs in treatment.